Abstract
PRM115 - Three-Monthly Long-Acting Formulation of Paliperidone Palmitate is a Dominant Treatment Option, Cost Saving While Adding Qalys, Compared to the One-Monthly Formulation in the Treatment of Schizophrenia in France
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
